About Citidaron
About Citidaron
CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking.1 The treatment goal of CITIDARON® is the permanent cessation of the nicotine-containing products use.1
Citidaron does not contain nicotine and has a favourable tolerability profile.
One Pack, One Prescription1
Simplifies prescribing and dispensing, supporting immediate patient access while reducing administrative burden.
Structured 25-day Treatment Course1
A short, structured treatment designed to support patients through the critical early phase of quitting.
GMS Reimbursed 2
An accessible prescription option for those motivated to quit.
Trusted in Smoking Cessation Across Europe for Over 50 Years3
A valuable alternative for patients seeking to quit without nicotine or long-term therapies
References
- CITIDARON® Summary of Product Characteristics, Consilient Health 2025.
- Citidaron®, HSE reimbursable item. Available here
- Karnieg T, Wang X. CYTISINE for smoking cessation CMAJ2018;190(19):E596
Safety Profile
Get an overview of the safety data and tolerability of Citidaron.
Taking Citidaron®
See the step-by-step course for taking Citidaron
Resources for you
Find additional support and information to help your patients succeed
Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie. Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.
The information on this website is intended for Health Care Professional who practice in the Republic of Ireland only
Sign up to stay informed about upcoming webinars
IE-CH-1730(1), March 2026